Biafine, a leading wound, radiodermatitis and burn care product in Europe, has been used for more than two decades by physicians, fire departments, emergency room personnel and radiation therapy facilities.
Healing results from a complex series of cellular and biochemical processes. Macrophages are cells which aid the healing process in several ways, including the removal of foreign particles and microorganisms. Macrophages occur in the walls of blood vessels and are usually immobile until stimulated by inflammation resulting from a wound or infection.
The healing process consists of three phases: 1) inflammation, during which macrophages assist in autolytic debridement, the removal of dead cells and tissue debris from the wound site; 2) proliferation, in which macrophages stimulate the production and activity of fibroblasts, cells responsible for the production of materials essential to healing such as collagen; and 3) maturation, when fibroblast proliferation promotes multiplication and growth of skin cells through chemical messengers such as fibroblast growth factor and macrophage-derived growth factor.
The unique formulation of Biafine recruits macrophages to the wound site during all three phases.
Biafine WDE can be used for a variety of full and partial thickness dermal wounds, including dermal, vascular, arterial, diabetic and pressure ulcers, as well as first and second degree burns. The product is a fluid, yet firm, emulsion that will conform to the contours of a wound and is available in 45-ml and 100-ml tubes. Biafine WDE can be used safely with topical antibiotics.
According to the most recent data available from the National Center for Health Statistics, in 1992, there were a total of 34 million emergency room visits that were injury-related, generating over $9.2 billion US in healthcare costs. Wound care was performed at approximately one-third of these visits.
In addition to wounds resulting from surgery or injury, Biafine WDE can be used for dermal ulcers, which are open sores on any external surface of the body. Diabetics often suffer from dermal ulcers, usually on their feet. Biafine WDE can also be used for pressure ulcers, known more commonly as bedsores. Pressure ulcers occur in five to nine percent of all hospitalized patients and in 23 percent of all nursing home patients.
Biafine WDE can also be used for chronic or delayed healing wounds. Application of Biafine WDE can renew the healing process in wounds that have not yet healed for years.
In addition, Biafine WDE can be used for the management of first and second degree burns. First degree burns are classified as those that involve only the epidermis (outermost layer of the skin) and are most commonly the result of overexposure to ultraviolet radiation, such as sunburn. Second degree burns are usually flash burns or the result of scalds.
Radiation therapy is used to treat many kinds of cancer in almost any part of the body. One common side effect of radiation therapy is radiodermatitis, in which the skin in the treatment area begins to look reddened, irritated or burned. Radiation-treated skin may also develop a moist reaction, especially where there are skin folds and may become very sore. Patients given radiation therapy for breast cancer are especially at risk for radiodermatitis. Biafine RE is available in 45-ml and 20-ml tubes as a prophylaxis against radiodermatitis and for the management of the condition.
If a skin reaction occurs after radiation therapy, Biafine RE can be applied as a wound dressing to manage radiodermatitis. In more severe cases of radiodermatitis, it should be applied in thick layers and may be covered with a gauze dressing if necessary.
Users browsing this forum: No registered users and 0 guests